Negatively supercoiled, relaxed and linearized forms of pSP73 DNA were modified in cell-free medium by cis-diamminedichloroplatinum(II) (cisplatin). The frequency of interstrand cross-links (ICLs) formed in these DNAs has been determined by: (i) immunochemical analysis; (ii) an assay employing NaCN as a probe of DNA ICLs of cisplatin; (iii) gel electrophoresis under denaturing conditions. At low levels of the modification of DNA (<1 Pt atom fixed per 500 bp) the number of ICLs formed by cisplatin was radically enhanced in supercoiled in comparison with linearized or relaxed DNA. At these low levels of modification, the frequency of ICLs in supercoiled DNA was enhanced with increasing level of negative supercoiling or with decreasing level of modification. In addition, the replication mapping of DNA ICLs of cisplatin was consistent with these lesions being preferentially formed in negatively supercoiled DNA between guanine residues in both the 5'-d(GC)-3' and the 5'-d(CG)-3' sites. Among the DNA adducts of cisplatin the ICL has the markedly greatest capability to unwind the double helix. We suggest that the formation of ICLs of cisplatin is thermodynamically more favored in negatively supercoiled DNA owing mainly to the relaxation of supercoils.

Institute of Biophysics Academy of Sciences of the Czech Republic Brno

See more in PubMed

Biochemistry. 1989 Feb 21;28(4):1454-61 PubMed

Cancer Res. 1979 Feb;39(2 Pt 1):365-9 PubMed

Biophys Chem. 1990 Apr;35(2-3):179-88 PubMed

Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 PubMed

Biochemistry. 1990 Oct 16;29(41):9522-31 PubMed

EMBO J. 1991 Feb;10(2):387-95 PubMed

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982-5 PubMed

J Mol Biol. 1991 May 20;219(2):145-9 PubMed

Biochemistry. 1991 Aug 13;30(32):8026-35 PubMed

Crit Rev Biochem Mol Biol. 1991;26(2):151-226 PubMed

Cell. 1980 Oct;21(3):773-83 PubMed

Cancer Chemother Pharmacol. 1983;10(3):145-9 PubMed

Ann Intern Med. 1984 May;100(5):704-13 PubMed

Cancer Res. 1984 May;44(5):2043-51 PubMed

Cancer Res. 1987 Jan 1;47(1):31-6 PubMed

Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Dec;50(6):995-1007 PubMed

Pharmacol Ther. 1987;34(2):155-66 PubMed

Biochemistry. 1987 Nov 17;26(23):7229-34 PubMed

Proc Natl Acad Sci U S A. 1988 Jun;85(12):4158-61 PubMed

J Mol Biol. 1991 Sep 5;221(1):107-22 PubMed

Eur J Biochem. 1991 Nov 1;201(3):723-30 PubMed

Biochemistry. 1992 Mar 10;31(9):2508-13 PubMed

Biochem Pharmacol. 1992 Mar 17;43(6):1249-54 PubMed

Methods Enzymol. 1992;212:319-35 PubMed

Eur J Pharmacol. 1992 May 12;226(1):5-13 PubMed

Biochem Biophys Res Commun. 1992 Nov 30;189(1):111-8 PubMed

J Biol Chem. 1993 Feb 5;268(4):2649-54 PubMed

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5345-9 PubMed

Biochemistry. 1993 Nov 2;32(43):11676-81 PubMed

J Mol Biol. 1993 Nov 20;234(2):297-301 PubMed

Bioessays. 1994 Jan;16(1):59-68 PubMed

Biochemistry. 1994 May 10;33(18):5404-10 PubMed

Nucleic Acids Res. 1994 Jun 25;22(12):2311-7 PubMed

Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8147-51 PubMed

Nucleic Acids Res. 1994 Aug 11;22(15):3005-10 PubMed

Nucleic Acids Res. 1994 Sep 25;22(19):3834-9 PubMed

Cancer Res. 1994 Nov 15;54(22):5911-6 PubMed

IARC Sci Publ. 1994;(125):339-48 PubMed

Cancer Chemother Pharmacol. 1995;35(4):323-6 PubMed

Int J Cancer. 1995 Mar 3;60(5):725-9 PubMed

Int J Cancer. 1995 Jul 4;62(1):70-5 PubMed

Mutat Res. 1995 Sep;348(1):25-31 PubMed

Nature. 1995 Oct 19;377(6550):649-52 PubMed

Int J Cancer. 1995 Sep 15;62(6):717-23 PubMed

Biochemistry. 1995 Sep 26;34(38):12369-78 PubMed

Biochemistry. 1995 Nov 28;34(47):15480-6 PubMed

Science. 1995 Dec 15;270(5243):1842-5 PubMed

Biochem Pharmacol. 1996 Mar 8;51(5):629-34 PubMed

Biochem Pharmacol. 1996 Mar 8;51(5):717-21 PubMed

Biochemistry. 1996 Feb 20;35(7):2180-8 PubMed

Biophys Chem. 1990 Apr;35(2-3):129-41 PubMed

The study of naphthoquinones and their complexes with DNA by using Raman spectroscopy and surface enhanced Raman spectroscopy: new insight into interactions of DNA with plant secondary metabolites

Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes

Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups

DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands